Počet záznamov: 1
alemtuzumab
SYS d000074323 LBL 00000nz--a2200181n--4500 005 20260512091234.6 008 180101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.313 065 $a D12.776.124.790.651.114.224.060.375 065 $a D12.776.377.715.548.114.224.200.375 066 $a 01 $c 03 150 $a alemtuzumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a protilátka monoklonálna Campath-1H $2 slo 450 $w v $a Lemtrada $2 slo 550 $7 sllk_us_auth*d000074322 $Y Antineoplastic Agents, Immunological $w P $a antineoplastiká imunologické 550 $7 sllk_us_auth*d000074301 $Y CD52 Antigen $w p $a antigén CD52 665 $a 2018 (1995) $2 eng 680 9-
$i An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY. $2 eng 750 -2
$a Alemtuzumab $2 eng 980 $x M
Počet záznamov: 1